Abstract

Vedolizumab has become an integral part of the therapeutic armamentarium for patients with inflammatory bowel disease (IBD) who have failed conventional medical therapy. Vedolizumab is an α4β7 integrin antagonist that inhibits intestinal T-cell translocation by blocking integrin interactions with mucosal vascular addressin cellular adhesion molecule 1, reducing lymphocyte-mediated inflammation.

Tags

Complications, Inflammatory Bowel Disease, IBD, Drug Therapy, therapeutic use, Gastrointestinal Agents, Antibodies, Monoclonal, Pharmacology

Read More